-
Something wrong with this record ?
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
A. Poprach, R. Lakomy, Z. Bortlicek, B. Melichar, T. Pavlik, O. Slaby, R. Vyzula, M. Svoboda, I. Kiss, H. Studentova, M. Zemanova, O. Fiala, K. Kubackova, L. Dusek, J. Hornova, T. Buchler, . ,
Language English Country New Zealand
Document type Journal Article
Grant support
NV15-34678A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
ProQuest Central
from 2008-06-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest)
from 2008-06-01 to 1 year ago
Psychology Database (ProQuest)
from 2008-06-01 to 1 year ago
- MeSH
- Time-to-Treatment MeSH
- Indoles administration & dosage adverse effects therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy pathology MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Kidney Neoplasms drug therapy pathology MeSH
- Disease-Free Survival MeSH
- Disease Progression MeSH
- Antineoplastic Agents administration & dosage adverse effects therapeutic use MeSH
- Pyrroles administration & dosage adverse effects therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Age Factors MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. PATIENTS AND METHODS: The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged <70 and ≥70 years, respectively. RESULTS: Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged <70 and ≥70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. CONCLUSIONS: The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031499
- 003
- CZ-PrNML
- 005
- 20201116155129.0
- 007
- ta
- 008
- 171025s2016 nz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40266-016-0390-1 $2 doi
- 035 __
- $a (PubMed)27541802
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 245 10
- $a Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice / $c A. Poprach, R. Lakomy, Z. Bortlicek, B. Melichar, T. Pavlik, O. Slaby, R. Vyzula, M. Svoboda, I. Kiss, H. Studentova, M. Zemanova, O. Fiala, K. Kubackova, L. Dusek, J. Hornova, T. Buchler, . ,
- 520 9_
- $a BACKGROUND: Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. PATIENTS AND METHODS: The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged <70 and ≥70 years, respectively. RESULTS: Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged <70 and ≥70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. CONCLUSIONS: The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
- 650 _2
- $a Česká republika $7 D018153
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007211
- 650 _2
- $a nádory ledvin $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a pyrroly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011758
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a čas zasáhnout při rozvinutí nemoci $7 D061665
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lakomy, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Pavlik, Tomas $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Slaby, Ondrej $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Vyzula, Rostislav $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapy, University Hospital, Pilsen, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Kubackova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Hornová, Jana, $d 1981- $7 xx0224781 $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, Prague, 140 59, Czech Republic.
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, Prague, 140 59, Czech Republic. tomas.buchler@ftn.cz.
- 700 1_
- $a ,
- 773 0_
- $w MED00001454 $t Drugs & aging $x 1179-1969 $g Roč. 33, č. 9 (2016), s. 655-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27541802 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20201116155127 $b ABA008
- 999 __
- $a ok $b bmc $g 1255092 $s 992526
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 33 $c 9 $d 655-63 $i 1179-1969 $m Drugs &aging $n Drugs Aging $x MED00001454
- GRA __
- $a NV15-34678A $p MZ0
- LZP __
- $a Pubmed-20171025
